Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis

Aún no traducido Aún no traducido
Autores
Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2000

Este artículo no está incluido en ninguna revisión sistemática

Este artículo es parte de los siguientes hilos de publicación
  • PREMIER - DE013 [The Prospective Multi-Centre Randomised, Double-Blind, Active Comparator-Controlled, Parallel-Groups Study Comparing the Fully Human Monoclonal Anti-TNFα Antibody Adalimumab Given Every Second Week With Methotrexate Given Weekly and the Combination of Adalimumab and Methotrexate Administered Over 2 Years in Patients With Early Rheumatoid Arthritis] (14 documentos)
Cargando información sobre las referencias
The purpose of the study is to assess the safety and efficacy of adalimumab in combination with methotrexate in patients with recent onset rheumatoid arthritis (RA), and to assess the long-term safety and maintenance of efficacy after treatment with adalimumab for up to 10 years.
Epistemonikos ID: 2d45460a0941742e1cc84586401120f68fb137a8
First added on: Jan 18, 2019